1. 无辅是什么意思
1. 结果：全组总的5年生存率为43.4%；术后病理分期(pathological TNM，pTNM)Ⅰ、Ⅱ、Ⅲ、Ⅳ期的患者5年生存率分别为75.6%、58.7%、28.0%、18.4%(P.01)；肿瘤大小＜2.0cm、2.0~3.9cm、4.0~5.9cm、6.0~7.9cm、≥8.0cm组的患者5年生存率分别为82.0%、57.4%、43.7%、38.7%、26.9%(P.05)；有、无辅加围手术期化疗的患者5年生存率分别为47.2%和37.8%。
The 5-year survival rates of patients in pathologic TNM stage Ⅰ, Ⅱ, Ⅲ, and Ⅳ were 75.6%, 58.7%, 28.0%, and 18.4%, repectively (P.01). The 5-year survival rates of patients with tumor sizes of less than 2.0 cm, 2.0-3.9 cm, 4.0-5.9 cm, 6.0-7.9 cm, and no less than 8.0cm were 82.0%, 57.4%, 43.7%, 38.7%, and 26.9%, respectively (P.05). In addition, the 5-year survival rate was higher in patients with perioperative chemotherapy than in patients without perioperative chemotherapy 47.2% vs.
2. 有、无辅加围手术期化疗的患者5年生存率分别为47.2%和37.8%。
In addition, the 5-year survival rate was higher in patients with perioperative chemotherapy than in patients without perioperative chemotherapy (47.2% vs. 37.8%, P < 0.05).
3. 无辅
3. 有、无辅加围手术期化疗的患者5年生存率分别为47.2%和37.8%。
In addition, the 5-year survival rate was higher in patients with perioperative chemotherapy than in patients without perioperative chemotherapy (47.2 % vs. 37.8 %, P < 0.05).